Statin Use Is Associated With Reduced Risk of Histologic Subtypes of Esophageal Cancer: A Nested Case-Control Analysis

摘要: Background & Aims Most patients with esophageal adenocarcinoma (EAC) or squamous cell cancer (ESCC) present advanced, incurable disease. Statins have reported anti-carcinogenic effects and may be chemoprotective. We investigated the association between regular use of statins main histologic subtypes malignancy (EAC, esophagogastric junctional adenocarcinoma, ESCC) in UK general population. Methods identified all individuals General Practice Research Database diagnosed from 2000 through 2009. Patients were linked to National Cancer Registry confirm subtypes. Each patient was matched up 4 controls for age, sex, practice. performed a nested case-control analysis using conditional logistic regression estimate risk each subtype statin use, adjusted body mass index, smoking, alcohol intake, concomitant medications. Results In total, 581 participants EAC, 213 332 ESCC 2167, 783, 1242 controls, respectively. Regular inversely associated development EAC (odds ratio = 0.58; 95% confidence interval: 0.39−0.87) (with significant dose duration responses) 0.29; 0.09−0.92) high-dose only). Statin 1−4 years 0.51; 0.27−0.98). Conclusions population-based cohort, cancer. Randomized controlled trials are warranted determine whether chemopreventive high-risk groups.